medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 1

<< Back Next >>

Ann Hepatol 2016; 15 (1)

Biochemical non-invasive assessment of liver fibrosis cannot replace biopsy in HIV-HCV coinfected patients

Kliemann DA, Wolff FH, Tovo CV, Alencastro PR, Ikeda MLR, Brandão ABM, Barcellos N, Fuchs SC

Language: English
References: 43
Page: 27-32
PDF size: 144.08 Kb.


ABSTRACT

Background and rationale. The liver biopsy has been considered the gold standard for the diagnosis and quantification of fibrosis. However, this method presents limitations. In addition, the non-invasive evaluation of liver fibrosis is a challenge. The aim of this study was to validate the fibrosis cirrhosis index (FCI) index in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients, and compare to AST/ALT ratio (AAR), AST to platelet ratio index (APRI) and FIB-4 scores, as a tool for the assessment of liver fibrosis in coinfected patients. Material and methods. Retrospective cross sectional study including 92 HIV-HCV coinfected patients evaluated in two reference centers for HIV treatment in the Public Health System in Southern Brazil. Patients who underwent liver biopsy for any indication and had concomitant laboratory data in the 3 months prior to liver biopsy, to allow the calculation of studied noninvasive markers (AAR, APRI, FIB-4 and FCI) were included. Results. APRI ‹ 0.5 presents the higher specificity to detect no or minimal fibrosis, whereas APRI › 1.5 presents the best negative predictive value and FCI › 1.25 the best specificity to detect significant fibrosis. The values of noninvasive markers for each Metavir fibrosis stage showed statistically significant differences only for APRI. In conclusion, until better noninvasive markers for liver fibrosis are developed and validated for HIV-HCV coinfected patients, noninvasive serum markers should be used carefully in this population.


REFERENCES

  1. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15: 5-14.

  2. Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.

  3. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the DAD study. Arch Intern Med 2006; 166: 1632-41.

  4. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, Quiros-Roldan E, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24: 211-7.

  5. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.

  6. Rousselet MC, Michalak S, Dupre F. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64.

  7. D’Incao RB, Silva MC, Almeida PR, Renon VP, Tovo CV. Percutaneous liver biopsy - 2 decades of experience in a public hospital in the South of Brazil. Ann Hepatol 2013; 12: 876- 80.

  8. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver Biopsy. Hepatology 2009; 49: 1017-44. Doi 10.1002/hep.22742.

  9. Mehta SH, Buckle GC. Assessment of liver disease (noninvasive methods). Curr Opin HIV AIDS 2011; 6: 465-71. Doi: 10.1097/COH.0b013e32834b55c7. Review.

  10. Resino S, Asensio C, Bellón JM, Carmona R, Miralles P, López JC, Cosín J, et al. Diagnostic accuracy of the APRI, FIB-4, and the Forns index for predicting liver fibrosis in HIV/ HCV-coinfected patients: a validation study. J Infect 2011; 63: 402-5. Doi: 10.1016/j.jinf.2011.07.017 [Epub Aug 3, 2011].

  11. Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci 2011; 56: 3038-44 [Doi 10.1007/ s10620-011-1710-2].

  12. Paesa CR, Marcilla F, López G, Hueso E, Pascual A, Aguirre JM. Valoración de los modelos APRI y Forns para el diagnóstico no invasivo de fibrosis en pacientes con hepatitis C coinfectados y no coinfectados por VIH. An Med Interna 2007; 24: 369-74.

  13. Singal G, Thomassen LV, Gretch DR, Shuhart MC. Use of the AST to platelet ratio index in HCV/HIV co-infected Patients. Aliment Pharmacol Ther 2011; 33: 566-77.

  14. Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, Asad S, et al. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol 2011; 11: 44. Doi: 10.1186/1471- 230X-11-44.

  15. Wolff FH, Fuchs SC, Barcellos NN, de Alencastro PR, Ikeda ML, Brandão AB, Falavigna M, et al. Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates. PLoS One 2010; 5: e10494. Doi: 10.1371/journal.pone.0010494.

  16. Valle Tovo C, Alves de Mattos A, Ribeiro de Souza A, Ferrari de Oliveira Rigo J, Lerias de Almeida PR, Galperim B, Riegel Santos B. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int 2007; 27: 40-6.

  17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.

  18. Hoofnagle JH, Williams AL. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. Gastroenterology 1988; 95: 734-9.

  19. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3053-5.

  20. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.

  21. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski M, et al. APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.

  22. Hanley JA, Mc Neil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.

  23. Benhamou Y, Di Martino V, Bochet M. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus- coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-7.

  24. Martin-Carbonero L, Benhamou Y, Puoti M. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128-33.

  25. Poynard T, Ratziu V, Benmanov Y. Fibrosis in patients with chronic hepatitis C: Detection and significance. Semin Liver Dis 2000; 47-55.

  26. Friedman SL. Evaluation of fibrosis and hepatitis C. Am J Med 1999; 107: 27S-30S.

  27. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.

  28. Regev A, Berho M, Jeffers LJ. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.

  29. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.

  30. Persico M, Persico E, Suozzo R. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760-4.

  31. Prati D, Taioli E, Zanella A, Della-Torre E, Butelli S, Del Vecchio E, Vianello L, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.

  32. Schiavon L, Narciso-Schiavon JN, Carvalho-Filho RJ, Ferraz MLG, Silva AEB. Impact of CD4+ T-cell count on the performance of non-invasive fibrosis markers in HIV-HCV patients. Aliment Pharmacol Ther 2011; 33: 1173-4. Author reply 1174-5. Doi: 10.1111/j.1365-2036.2011.04613.x.

  33. Tural C, Tor J, Sanvisens A, Pérez-Alvarez A, Martinez E, Ojanguren I, Garcia-Samaniego J, et al. Accuracy of Simple Biochemical Tests in Identifying Liver Fibrosis in Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis C Virus. Clin Gastroenterol Hepatol 2009; 7: 339-45. Doi: 10.1016/j.cgh.2008.11.019 [Epub Dec 3, 2008].

  34. González-Guilabert MI, Hinojosa Mena-Bernal C, del Pozo González J, del Pozo Pérez MA. Retrospective study of FibroScan, APRI, FIB-4 and FORNS indexes compared with liver biopsy in the evaluation of liver fibrosis in patients with chronic hepatitis C monoinfection and HIV coinfection. Gastroenterol Hepatol 2010; 33: 425-32. Doi: 10.1016/ j.gastrohep.2010.02.005 [Epub May 14, 2010].

  35. Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, Sampaio JP, Lanzoni VP, Ferraz MLG, Silva AEB. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver International 2008; 28: 486-93. Doi: 10.1111/j.1478-3231.2008.01675.x.

  36. Castera L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, Asselineau J, et al. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med 2014; 15: 30-9. Doi: 10.1111/hiv.12082 [Epub Sep 6, 2013].

  37. Saadeh S, Cammell G, Carey WD. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200.

  38. Romagnuolo J, Jhangri GS, Jewell LD. Predicting the liver histology in chronic hepatitis C: How good is the clinician? Am J Gastroenterol 2001; 96: 3165-74.

  39. Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 2001; 8: 249-55.

  40. Forns X, Ampurdane’s S, Llovet JM. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.

  41. Li Vecchi V, Giannitrapani L, Di Carlo P, Mazzola G, Colletti P, La Spada E, Vizzini G, et al. Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV and HCV infectec patients. Ann Hepatol 2013; 12: 740-8.

  42. Caviglia GP, Ciancio A, Rosso C, Abate ML, Olivero A, Pellicano R, Touscoz GA, et al. Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. Ann Hepatol 2013; 13: 91-7. PMID: 24378271.

  43. Sanchez-Conde M, Montes-Ramírez M, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010; 17: 280-6.




2020     |     www.medigraphic.com